Robert Roskoski

List of Publications by Year
in descending order

56 papers	13,245 citations	61945 43 h-index	149623 56 g-index
58 all docs	58 docs citations	58 times ranked	18030 citing authors

#	Article	IF	Citations
1	Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update. Pharmacological Research, 2022, 175, 106037.	3.1	136
2	A Primer on BRIMR. American Journal of Pathology, 2022, 192, 392-394.	1.9	7
3	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia. Pharmacological Research, 2022, 178, 106156.	3.1	30
4	Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). Pharmacological Research, 2021, 165, 105422.	3.1	46
5	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. Pharmacological Research, 2021, 165, 105463.	3.1	242
6	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 2021, 168, 105579.	3.1	39
7	Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes. Pharmacological Research, 2021, 169, 105660.	3.1	16
8	Writing it right for Pharmacological Research. Pharmacological Research, 2021, 170, 105733.	3.1	0
9	Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS. Pharmacological Research, 2021, 172, 105806.	3.1	17
10	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacological Research, 2020, 152, 104609.	3.1	415
11	The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacological Research, 2020, 151, 104567.	3.1	88
12	NIH funding trends to US medical schools from 2009 to 2018. PLoS ONE, 2020, 15, e0233367.	1.1	17
13	The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Pharmacological Research, 2020, 155, 104725.	3.1	21
14	Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2019, 144, 19-50.	3.1	377
15	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. Pharmacological Research, 2019, 142, 151-168.	3.1	202
16	Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research, 2019, 139, 395-411.	3.1	315
17	Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharmacological Research, 2019, 139, 471-488.	3.1	270
18	The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 129, 65-83.	3.1	117

#	Article	IF	Citations
19	Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers. Pharmacological Research, 2018, 128, 1-17.	3.1	91
20	The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacological Research, 2018, 133, 35-52.	3.1	66
21	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
22	Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacological Research, 2017, 117, 343-356.	3.1	87
23	Guidelines for preparing color figures for everyone including the colorblind. Pharmacological Research, 2017, 119, 240-241.	3.1	94
24	ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Pharmacological Research, 2017, 121, 202-212.	3.1	93
25	Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacological Research, 2017, 120, 116-132.	3.1	184
26	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. Pharmacological Research, 2017, 117, 20-31.	3.1	78
27	Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms. Pharmacological Research, 2016, 113, 395-408.	3.1	70
28	Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological Research, 2016, 111, 784-803.	3.1	279
29	Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacological Research, 2016, 107, 249-275.	3.1	179
30	Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacological Research, 2016, 103, 26-48.	3.1	570
31	Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research, 2015, 94, 9-25.	3.1	416
32	Michaelis-Menten Kineticsâ˜†. , 2015, , .		13
33	A historical overview of protein kinases and their targeted small molecule inhibitors. Pharmacological Research, 2015, 100, 1-23.	3.1	391
34	The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological Research, 2014, 79, 34-74.	3.1	1,028
35	Complex molecular regulation of tyrosine hydroxylase. Journal of Neural Transmission, 2014, 121, 1451-1481.	1.4	97
36	ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors. Pharmacological Research, 2014, 87, 42-59.	3.1	161

#	Article	IF	Citations
37	The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opinion on Drug Discovery, 2013, 8, 1165-1179.	2.5	32
38	Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. Pharmacological Research, 2013, 68, 68-94.	3.1	238
39	ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research, 2012, 66, 105-143.	3.1	1,246
40	MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2012, 417, 5-10.	1.0	213
41	RAF protein-serine/threonine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2010, 399, 313-317.	1.0	296
42	VEGF receptor proteinâ€“tyrosine kinases: Structure and regulation. Biochemical and Biophysical Research Communications, 2008, 375, 287-291.	1.0	228
43	Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochemical and Biophysical Research Communications, 2007, 356, 323-328.	1.0	342
44	Vascular endothelial growth factor (VEGF) signaling in tumor progression. Critical Reviews in Oncology/Hematology, 2007, 62, 179-213.	2.0	515
45	Src kinase regulation by phosphorylation and dephosphorylation. Biochemical and Biophysical Research Communications, 2005, 331, 1-14.	1.0	501
46	Signaling by Kit protein-tyrosine kinaseâ€”The stem cell factor receptor. Biochemical and Biophysical Research Communications, 2005, 337, 1-13.	1.0	258
47	Structure and regulation of Kit protein-tyrosine kinaseâ€”The stem cell factor receptor. Biochemical and Biophysical Research Communications, 2005, 338, 1307-1315.	1.0	299
48	The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochemical and Biophysical Research Communications, 2004, 319, 1-11.	1.0	349
49	Src proteinâ€“tyrosine kinase structure and regulation. Biochemical and Biophysical Research Communications, 2004, 324, 1155-1164.	1.0	471
50	STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications, 2003, 309, 709-717.	1.0	101
51	Protein prenylation: a pivotal posttranslational process. Biochemical and Biophysical Research Communications, 2003, 303, 1-7.	1.0	141
52	Role of the Carboxyterminal Residue in Peptide Binding to Protein Farnesyltransferase and Protein Geranylgeranyltransferase. Archives of Biochemistry and Biophysics, 1998, 356, 167-176.	1.4	35
53	Fritz Lipmann (1899â€“1986): an appreciation. Trends in Biochemical Sciences, 1987, 12, 136-138.	3.7	3
54	[1] Assays of protein kinase. Methods in Enzymology, 1983, 99, 3-6.	0.4	803

#	Article	IF	Citations
55	Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit. Biochemistry, 1982, 21, 5794-5799.	1.2	403
56	Rapid protein kinase assay using phosphocellulose-paper absorption. Analytical Biochemistry, 1975, 66, 253-258.	1.1	360